Pfizer, Genesys invest in natural-product drug maker Adapsyn
Adapsyn Bioscience Inc, a Hamilton, Ontario biotechnology company focused on natural-product drug candidates, has wrapped up an undisclosed round of financing. The deal was co-funded by Pfizer R&D Innovate, an affiliate of U.S. pharmaceutical giant Pfizer Inc, and Genesys Capital, a Canadian life sciences venture capital firm. Genesys Managing Director Kelly Holman currently sits on the board. Adapsyn also announced it is partnering with Pfizer to identify and test undiscovered natural products, or organic biomolecules produced by nature, from Pfizer's microbial strains. Adapsyn was founded in 2016 by CSO Nathan Magarvey.
9 January 2018•3 mins read
